Table 1.
Baseline characteristics of patients according to glycemic category and treatment group
| Characteristic | Normoglycemia (N = 3,950) | Prediabetes (N = 6,695) | Diabetes (N = 5,141) | |||
|---|---|---|---|---|---|---|
| Dalcetrapib n = 1,932 | Placebo n = 2,018 | Dalcetrapib n = 3,394 | Placebo n = 3,301 | Dalcetrapib n = 2,573 | Placebo n = 2,568 | |
| Age, years*†‡ | 58.6 (8.7) | 58.6 (8.8) | 59.9 (9.1) | 60.0 (9.0) | 61.8 (9.1) | 61.4 (9.2) |
| Male sex (%)*†‡ | 82.9 | 84.2 | 80.7 | 81.7 | 77.4 | 78.0 |
| White race (%)*†‡ | 92.5 | 92.0 | 89.1 | 89.2 | 83.9 | 84.5 |
| History of hypertension (%)*†‡ | 58.6 | 60.8 | 62.3 | 63.0 | 80.3 | 81.2 |
| Current smoking (%)‡ | 18.7 | 18.6 | 22.8 | 23.4 | 20.4 | 19.3 |
| Prior myocardial infarction (%)*† | 12.0 | 11.6 | 14.5 | 14.0 | 21.2 | 19.4 |
| Prior stroke (%) | 2.6 | 2.7 | 2.6 | 2.6 | 4.8 | 5.1 |
| Blood pressure, mmHg | ||||||
| Systolic*†‡ | 125.5 (16.6) | 125.6 (16.7) | 126.8 (16.9) | 127.1 (16.6) | 130.0 (17.1) | 129.7 (17.1) |
| Diastolic | 76.8 (9.6) | 76.6 (9.8) | 76.9 (9.8) | 77.0 (9.6) | 77.1 (9.9) | 76.8 (9.6) |
| BMI, kg/m2*†‡ | 27.5 (4.5) | 27.4 (4.1) | 28.1 (4.6) | 28.2 (4.5) | 30.1 (5.3) | 30.2 (5.7) |
| Laboratory tests | ||||||
| Fasting serum glucose, mmol/L*†‡ | 5.17 (0.53) | 5.18 (0.53) | 5.43 (0.60) | 5.45 (0.59) | 7.20 (2.40) | 7.18 (2.32) |
| Hemoglobin A1c, %*†‡ | 5.34 (0.23) | 5.35 (0.22) | 5.85 (0.24) | 5.84 (0.24) | 6.82 (1.07) | 6.80 (1.07) |
| Total cholesterol, mg/dL†‡ | 143.9 (30.6) | 142.4 (31.5) | 148.0 (33.6) | 147.1 (31.9) | 143.4 (34.0) | 142.5 (33.5) |
| LDL-C, mg/dL*†‡ | 75.3 (24.1) | 74.7 (24.8) | 78.8 (27.1) | 78.2 (24.9) | 74.1 (26.8) | 73.4 (27.6) |
| HDL-C, mg/dL*†‡ | 44.2 (12.6) | 43.4 (12.2) | 43.0 (11.4) | 42.7 (11.2) | 40.6 (11.2) | 40.5 (11.2) |
| Triglycerides, mg/dL*†‡ | 123 (69) | 122 (62) | 132 (71) | 132 (74) | 145 (78) | 143 (80) |
| eGFR, mL/min/1.7 m2*† | 81.9 (16.6) | 82.6 (17.4) | 81.9 (17.0) | 81.9 (17.2) | 80.6 (21.5) | 80.9 (20.4) |
| Medications (%) | ||||||
| Aspirin or other antiplatelet agent† | 99.2 | 99.3 | 99.2 | 99.6 | 98.8 | 98.9 |
| ACE inhibitor or ARB*†‡ | 73.8 | 72.7 | 78.6 | 79.1 | 84.7 | 84.2 |
| β-Blocker*† | 86.6 | 87.1 | 86.8 | 87.1 | 88.4 | 88.7 |
| Statin*† | 97.5 | 98.1 | 97.6 | 97.8 | 96.7 | 96.8 |
Data are mean (SD) unless otherwise indicated. All characteristics were balanced between the dalcetrapib and placebo groups (P > 0.05). BMI data missing for 27 patients (0.7%) with normoglycemia, 33 patients (0.5%) with prediabetes, and 44 patients (0.9%) with diabetes. Some laboratory data missing for 5 patients (0.1%) with normoglycemia, 5 patients (0.1%) with prediabetes, and 40 patients (0.8%) with diabetes. An additional 85 patients (0.5%) had insufficient glucose and hemoglobin A1c data to determine baseline glycemic status and are not included in this table or in the analyses. ARB, angiotensin II receptor blocker; eGFR, estimated glomerular filtration rate.
P < 0.05 for difference between normoglycemia and diabetes;
P < 0.05 for difference between prediabetes and diabetes;
P < 0.05 for difference between normoglycemia and prediabetes, comparing the aggregate of both treatment groups in each metabolic category.